Verantos Announces Collaboration with Nashville Biosciences to Power Advanced Real-World Evidence Studies

PALO ALTO, Calif., Aug. 5, 2021 /PRNewswire/ — Verantos, the market leader in high-validity, real-world evidence (RWE) generation, today announced a collaboration with Nashville Biosciences focused on the use of curated data sources and artificial intelligence (AI) to power advanced RWE studies.

Verantos, Palo Alto, California. (PRNewsfoto/Verantos)

The collaboration leverages Nashville Biosciences’ clinical and genomic database of more than three million de-identified longitudinal medical records and over 260,000 linked genetic samples with Verantos’ technological expertise to develop data sets enriched with AI-generated insights.

“We appreciate the commitment Nashville Biosciences has shown towards innovation in advanced RWE,” said Anand Shroff, President of Verantos. “This collaboration will produce research-grade data sets useful for regulatory and reimbursement purposes.”

The enriched data sets contain insights that allow for a better understanding of population characteristics, natural history of disease, and treatment patterns, but allow Nashville Biosciences to maintain control of the underlying clinical source data.

Leeland Ekstrom, Chief Operating Officer of Nashville Biosciences, stated this relationship will accelerate research that ultimately benefits patients. “Much of the R&D value in electronic medical records is the phenotypes that exist within the rich diversity of data they contain. We are excited to work with Verantos and use their technology to leverage this diversity of data at a much larger scale to accelerate the pace of discovery for our clients.”

The two companies will collaborate across therapeutic areas, initially focusing on developing heart failure and asthma cohorts.

About Verantos:

Verantos is the market leader in high-accuracy real-world evidence generation. The Verantos RWE platform integrates heterogeneous real-world data sources and generates evidence with the accuracy necessary for regulatory and reimbursement use. The Verantos RWE platform leverages data science and artificial intelligence along with advanced data sources such as electronic health records to generate RWE capable of supporting clinical assertions.

About Nashville Biosciences

Nashville Biosciences, a wholly owned subsidiary of Vanderbilt University Medical Center (VUMC), was created to harness the VUMC’s extensive genomic and bioinformatics resources for drug and diagnostics discovery and development. Leveraging Vanderbilt University Innovation, Nashville Biosciences serves as a commercial interface between outside companies and the formidable research capabilities represented by BioVU®, one of the world’s most comprehensive genetic databases linked to de-identified medical records with years of longitudinal clinical data. This unique asset is one of the largest and highest quality of its kind, providing an unprecedented opportunity to guide R&D activity in biotech, pharma, diagnostics, medical devices, and other life sciences applications.

Contact: Amy Roberts

Email: [email protected]

Phone: 435-659-1164

Cision View original content to download multimedia:

SOURCE Verantos

Disclaimer: The above press release comes to you under an arrangement with PR Newswire. takes no editorial responsibility for the same.

Readers like you help support The Tech Outlook. When you make a purchase using links on our site, we may earn an affiliate commission. We cannot guarantee the Product information shown is 100% accurate and we advise you to check the product listing on the original manufacturer website. Thetechoutlook is not responsible for price changes carried out by retailers. The discounted price or deal mentioned in this item was available at the time of writing and may be subject to time restrictions and/or limited unit availability. Amazon and the Amazon logo are trademarks of, Inc. or its affiliates Read More


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More